PL4146659T3 - Pierścieniowo skondensowane związki 2-pirydonowe, sposoby ich wytwarzania i ich zastosowanie w leczeniu i/lub zapobieganiu chorobie z udziałem bakterii gram-dodatnich - Google Patents

Pierścieniowo skondensowane związki 2-pirydonowe, sposoby ich wytwarzania i ich zastosowanie w leczeniu i/lub zapobieganiu chorobie z udziałem bakterii gram-dodatnich

Info

Publication number
PL4146659T3
PL4146659T3 PL21724674.3T PL21724674T PL4146659T3 PL 4146659 T3 PL4146659 T3 PL 4146659T3 PL 21724674 T PL21724674 T PL 21724674T PL 4146659 T3 PL4146659 T3 PL 4146659T3
Authority
PL
Poland
Prior art keywords
fused
prevention
preparation
treatment
ring
Prior art date
Application number
PL21724674.3T
Other languages
English (en)
Inventor
Fredrik Almqvist
Pardeep SINGH
Original Assignee
Quretech Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quretech Bio Ab filed Critical Quretech Bio Ab
Publication of PL4146659T3 publication Critical patent/PL4146659T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL21724674.3T 2020-05-08 2021-05-07 Pierścieniowo skondensowane związki 2-pirydonowe, sposoby ich wytwarzania i ich zastosowanie w leczeniu i/lub zapobieganiu chorobie z udziałem bakterii gram-dodatnich PL4146659T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2050543 2020-05-08
PCT/EP2021/062237 WO2021224501A1 (en) 2020-05-08 2021-05-07 Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria

Publications (1)

Publication Number Publication Date
PL4146659T3 true PL4146659T3 (pl) 2025-06-23

Family

ID=75888058

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21724674.3T PL4146659T3 (pl) 2020-05-08 2021-05-07 Pierścieniowo skondensowane związki 2-pirydonowe, sposoby ich wytwarzania i ich zastosowanie w leczeniu i/lub zapobieganiu chorobie z udziałem bakterii gram-dodatnich

Country Status (8)

Country Link
US (1) US12503476B2 (pl)
EP (1) EP4146659B1 (pl)
JP (1) JP7741817B2 (pl)
CN (1) CN115551869B (pl)
DK (1) DK4146659T3 (pl)
ES (1) ES3017588T3 (pl)
PL (1) PL4146659T3 (pl)
WO (1) WO2021224501A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841559B1 (en) * 1999-11-19 2005-01-11 Washington University Of St. Louis Pyridinones to treat and prevent bacterial infections
WO2014185853A1 (en) 2013-05-14 2014-11-20 Quretech Bio Ab Compounds and methods for treatment of chlamydia infections
US10294244B2 (en) * 2014-11-13 2019-05-21 Quretech Bio Ab 2,3-dihydro-thiazolo[3,2-A]pyridin-5-one derivatives, intermediates thereof, and their use as antibacterial agents
CN109069492B (zh) * 2016-04-08 2021-12-10 快尔生物技术公司 环稠和的噻唑啉2-吡啶酮、其制备方法及其在治疗和/或预防结核中的用途
CN110799513B (zh) * 2017-06-13 2023-04-14 快尔生物技术公司 环稠合噻唑并-2-吡啶酮、其制备方法及其治疗和/或预防涉及革兰氏阳性菌的疾病的应用
WO2019068910A1 (en) * 2017-10-05 2019-04-11 Quretech Bio Ab THIAZOLINO 2-PYRIDONES WITH A FUSED CYCLE IN COMBINATION WITH A MEDICINE AGAINST TUBERCULOSIS

Also Published As

Publication number Publication date
WO2021224501A1 (en) 2021-11-11
US12503476B2 (en) 2025-12-23
JP2023525280A (ja) 2023-06-15
CN115551869A (zh) 2022-12-30
US20230339973A1 (en) 2023-10-26
ES3017588T3 (en) 2025-05-13
EP4146659B1 (en) 2025-02-26
JP7741817B2 (ja) 2025-09-18
CN115551869B (zh) 2024-01-02
EP4146659A1 (en) 2023-03-15
DK4146659T3 (en) 2025-04-14

Similar Documents

Publication Publication Date Title
WO2009088549A3 (en) Methods of inhibiting bacterial virulence and compounds relating thereto
IL268960A (en) 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome
PH12018501221A1 (en) Mixture of hmos
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
PT2748165T (pt) Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
WO2016109684A3 (en) Derivatives and methods of treating hepatitis b infections
BR112012001987A2 (pt) Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase.
PH12019500083A1 (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
SG10202002898RA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
WO2015110969A3 (en) Nitrogen containing compounds and their use as antibacterial agents
ZA202008040B (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
DK3292867T3 (da) Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
IL312625A (en) Crystalline compounds of imidazo[5,4-b]pyridine, pharmaceutical compositions, and their uses in the treatment of medical conditions
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
CN110062806A (zh) 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
DK4146659T3 (en) Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria
WO2017158616A8 (en) Carbapenem compounds
SG11202102790PA (en) Indane derivatives for use in the treatment of bacterial infection
BRPI0610722A2 (pt) métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição